What Happens When You Stop the Medication
Semaglutide and tirzepatide have produced some of the most significant clinical weight loss results ever seen in large-scale trials. But a major new analysis now quantifies what happens when patients stop taking them, and the findings are prompting clinicians and patients to rethink what these medications are actually designed to do.
An Oxford University systematic review published in January 2026 tracked more than 9,341 adults across 37 studies who stopped taking weight management medicines. The average weight regain across all medications was about 0.4 kg (roughly 0.9 pounds) per month after stopping. For people who had been taking the newer GLP-1 drugs — semaglutide (sold as Ozempic and Wegovy) and tirzepatide (sold as Mounjaro and Zepbound) — the rate of regain was nearly double: approximately 0.8 kg, or roughly 1.8 pounds, per month.
At that pace, the Oxford team projected that patients who stop semaglutide or tirzepatide would return to their starting weight within approximately 18 months.
Why This Matters
The weight loss potential of GLP-1 medications has been widely reported. The implication of these new findings is less discussed: these drugs may function more like insulin for diabetes — a long-term therapy that manages a chronic condition — than like a course of antibiotics that achieves a permanent result.
For patients who are currently on these medications or considering them, the Oxford data raises a practical and financially significant question: how long will I need to stay on this treatment to keep the weight off? For many Americans, GLP-1 drugs cost between $800 and $1,300 per month without insurance coverage, a figure that makes indefinite use inaccessible for large portions of the population.
The answer, based on current evidence, is that most patients will regain substantial weight after stopping unless they either restart the medication or pursue alternative strategies.
What We Know So Far
The Oxford team's systematic review included participants who had been on weight management medicines for an average of 39 weeks before stopping and were then followed for an average of 32 weeks afterward. Three different statistical approaches were used, and all three produced consistent results.
Lead investigator Dr. Sam West of the University of Oxford told TCTMD that the magnitude of regain was surprising: "While people lose around 15 kilograms using semaglutide and tirzepatide, they've gained nearly 10 kilograms within the first year [after stopping]." That represents a regain of roughly two-thirds of the original weight loss within 12 months of discontinuation — a figure consistent with the STEP 1 trial extension data, which found similar results in patients who stopped semaglutide in a randomized trial setting.
A separate finding in the Oxford review was also notable: weight regain after stopping GLP-1 medications was faster than after ending a behavioral weight loss program — diet and exercise support — by approximately 0.3 kg (0.7 pounds) per month, independent of how much weight was initially lost. That comparison matters because it suggests that the physiological changes produced by GLP-1 medications may create a rebound effect that behavioral programs do not.
What Real-World Data Shows
The Oxford systematic review reflects trial-style discontinuation. A separate real-world analysis offers a more nuanced picture — though it does not change the overall conclusion.
A Cleveland Clinic study of 7,938 patients published in the journal Diabetes, Obesity and Metabolism in March 2026 found that many patients who stopped semaglutide or tirzepatide in clinical practice regained less weight than trial participants, because a significant proportion of them restarted the medication or transitioned to another obesity treatment rather than simply going without.
"Our real-world data show that many patients who stop semaglutide or tirzepatide restart the medication or transition to another obesity treatment, which may explain why they regain less weight than patients in randomized trials," said Dr. Hamlet Gasoyan of the Cleveland Clinic. The Cleveland data provide practical reassurance for patients who stop and restart, but they do not alter the conclusion for those who stop without any alternative treatment: weight regain is the expected outcome.
Who Faces the Greatest Risk?
Patients most likely to experience significant weight regain after stopping GLP-1 medications include:
- Adults who stop the medication without transitioning to a behavioral program or alternative treatment
- Patients who stopped due to cost or insurance coverage loss — a growing group as GLP-1 coverage remains inconsistent
- People who lost the largest amount of weight while on treatment (because they have the most to regain)
- Individuals who experienced remission of related conditions like sleep apnea or prediabetes, which may return with weight regain
- Patients in states where Medicaid does not yet cover GLP-1 medications for obesity
The research also found that adding behavioral support alongside medication was associated with greater weight loss during treatment — but it did not slow the rate of regain once the medication was stopped.
What the Evidence Shows and What It Does Not
MedicalDaily Evidence Check
- Study type: Systematic review and meta-analysis (Oxford); retrospective cohort study (Cleveland Clinic)
- Participants: 9,341 adults across 37 studies (Oxford); 7,938 patients (Cleveland Clinic)
- Published in: Oxford findings published January 2026; Cleveland Clinic findings published in Diabetes, Obesity and Metabolism, March 2026
- What it found: Stopping GLP-1 medications leads to rapid weight regain — approximately 1.8 pounds per month for semaglutide and tirzepatide users, with most lost weight regained within 18 months
- What it did not prove: The studies do not establish the minimum effective duration of treatment needed to produce lasting results after stopping. Long-term outcomes beyond 12–18 months after stopping remain understudied.
- What readers should know: These medications appear to manage obesity as a chronic condition rather than cure it. Patients and providers should discuss long-term treatment plans — including what happens if coverage is lost — before starting.
Symptoms and Warning Signs to Watch for After Stopping
People who stop GLP-1 medications and are monitoring for weight regain should watch for:
- Return of hunger and appetite at levels similar to before treatment started (a signal that the medication's appetite-suppression effect has worn off)
- Gradual weight gain over the first few months after stopping
- Return of conditions that improved with weight loss, such as elevated blood sugar, high blood pressure, or worsening sleep apnea
- Emotional distress related to weight regain, which is common and warrants a conversation with a provider or behavioral health professional
Weight regain after stopping is not a personal failure. It reflects the pharmacology of these medications, not a lack of willpower.
What You Can Do Now
- If you are currently on semaglutide or tirzepatide, do not stop without talking to your prescribing provider. Discuss what a long-term treatment plan looks like and what the alternatives are if cost or coverage changes.
- Ask your provider about combining behavioral weight management support with medication while you are on treatment. Structured programs may help sustain results over the long term.
- If your insurance coverage for GLP-1 medications has changed, ask your prescriber about patient assistance programs. Novo Nordisk and Eli Lilly both operate assistance programs for eligible patients.
- If you have already stopped and are experiencing weight regain, contact your provider to discuss whether restarting, transitioning to an alternative treatment, or enrolling in a behavioral program is appropriate for your situation.
- Do not start or stop these medications based on cost alone without reviewing alternatives with a clinician.
Cost and Access: What Patients Should Know
GLP-1 medications for weight loss remain expensive and inconsistently covered. Wegovy (semaglutide) and Zepbound (tirzepatide) list at approximately $1,000 to $1,300 per month without insurance. Medicare coverage for obesity treatments expanded in recent years, but coverage varies by plan and state. Many employer insurance plans still exclude GLP-1 medications for weight loss, even when they are covered for diabetes.
Patients experiencing coverage gaps can contact the Novo Nordisk Patient Assistance Program or the Eli Lilly Cares Foundation directly. Telehealth platforms offering compounded versions of semaglutide are not FDA-approved and carry safety risks — patients should use only FDA-approved formulations from licensed pharmacies.
What Happens Next
The Oxford research team noted that follow-up data beyond 12 months after stopping GLP-1 medications is limited, and longer-term studies are needed to understand whether any patients sustain meaningful weight loss after extended treatment periods. Several ongoing trials are examining whether intermittent dosing or maintenance strategies can reduce regain. Regulators and payers are also watching these data closely as they determine coverage policies.
The Bottom Line
The evidence now strongly supports treating GLP-1 medications as long-term therapy for obesity rather than as a course of treatment with a defined end date. For patients who need to stop — due to cost, side effects, or personal choice — the expected outcome is significant weight regain, likely within 18 months. Having that conversation with a provider before stopping, rather than after, gives patients the best chance of planning effectively.
